The ASCOT trial was a breakthrough observation where the newer hypotensive drugs proved superior to the older generation drugs in reducing cardio-vascular complications. Large clinical trials results, despite their influence on everyday practice, do not answer the question on long term benefits of a certain therapeutic approach. This question was raised in ASOCT-Legacy trial where the authors searched the answer if the initially started therapy influences the long term prognosis and if discovered amlodipine/perindopril combination advantage will persist for the long time and result in reducing patients’ mortality. The mortality analysis in ASCOT-Legacy trial patients, after on average of 16 years of observation, indicated to 29% reduction in number of stroke deaths in newer drugs group. At the same time the patients not included in the LLA arm benefited with 21% reduction in cardiovascular deaths and 24% reduction in coronary disease mortality.